

Special Issue

Immune Response after Vaccination against SARS-CoV-2 in Patients with Chronic Diseases

Message from the Guest Editor

This Special Issue aims to update the current knowledge and future directions of SARS-CoV-2 vaccination and management in patients with chronic medical conditions (patients with solid/hematological malignancies, those who have received organ transplants, patients on dialysis, those receiving immunosuppressive medications, elderly individuals, individuals with morbid obesity, and possibly other patient groups) **In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:**

- Immune response to SARS-CoV-2 vaccines in patients with chronic diseases.
- Vaccination strategy and vaccine classes (additional and booster vaccine shots, combination of vaccine classes).
- Efficacy of vaccination in patients with chronic medical conditions: laboratory and/or clinical evaluation.
- SARS-CoV-2 management of the immunocompromised beyond vaccination.
- Other related topics.

Guest Editor

Dr. Noa Berar Yanay

1. Head of Nephrology Department, Hillel Yaffe Medical Center, Hadera 38100, Israel
2. Rappaport Faculty of Medicine, Technion Israel, Haifa 32000, Israel

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/116293

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).